Добавил:
Upload Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Prescriber's Guide_ Stahl's Ess - Stephen M. Stahl.docx
Скачиваний:
1
Добавлен:
01.07.2025
Размер:
3 Мб
Скачать
☆

Other Warnings/Precautions

• Not recommended for use with sibutramine

• Use cautiously in patients with alcohol withdrawal or convulsive disorders because of possible lowering of seizure threshold

• If signs of neuroleptic malignant syndrome develop, treatment should be immediately discontinued

• Because zotepine may dose-dependently prolong QTc interval, use with caution in patients who have bradycardia or who are taking drugs that can induce bradycardia (e.g., beta blockers, calcium channel blockers, clonidine, digitalis)

• Because zotepine may dose-dependently prolong QTc interval, use with caution in patients who have hypokalemia and or hypomagnesemia or who are taking drugs than can induce hypokalemia and/or magnesemia (e.g., diuretics, stimulant laxatives, intravenous amphotericin B, glucocorticoids, tetracosactide)

• Because zotepine dose-dependently prolongs QTc interval, use with caution in patients taking any agent capable of increasing zotepine plasma levels (e.g., diazepam, CYP450 1A2 inhibitors, and CYP450 3A4 inhibitors)

Do Not Use

• If patient has epilepsy or family history of epilepsy

• If patient has gout or history of nephrolithiasis

• If patient is taking other CNS depressants

• If patient is taking high doses of other antipsychotics

• If patient is taking agents capable of significantly prolonging QTc interval (e.g., pimozide; thioridazine; selected antiarrhythmics such as quinidine, disopyramide, amiodarone, and sotalol; selected antibiotics such as moxifloxacin and sparfloxacin)

• If there is a history of QTc prolongation or cardiac arrhythmia, recent acute myocardial infarction, uncompensated heart failure

• If patient is pregnant or breast feeding

• If there is a proven allergy to zotepine

ZOTEPINE: SPECIAL POPULATIONS

Renal Impairment

• Recommended starting dose 25 mg twice a day; recommended maximum dose generally 75 mg twice a day

Hepatic Impairment

• Recommended starting dose 25 mg twice a day; recommended maximum dose generally 75 mg twice a day

• May require weekly monitoring of liver function during the first few months of treatment

Cardiac Impairment

• Drug should be used with caution

• Zotepine produces a dose-dependent prolongation of QTc interval, which may be enhanced by the existence of bradycardia, hypokalemia, congenital or acquired long QTc interval, which should be evaluated prior to administering zotepine

• Use with caution if treating concomitantly with a medication likely to produce prolonged bradycardia, hypokalemia, slowing of intracardiac conduction, or prolongation of the QTc interval

• Avoid zotepine in patients with a known history of QTc prolongation, recent acute myocardial infraction, and uncompensated heart failure

Elderly

• Recommended starting dose 25 mg twice a day; recommended maximum dose generally 75 mg twice a day

• Although atypical antipsychotics are commonly used for behavioral disturbances in dementia, no agent has been approved for treatment of elderly patients with dementia-related psychosis

• Elderly patients with dementia-related psychosis treated with atypical antipsychotics are at an increased risk of death compared to placebo, and also have an increased risk of cerebrovascular events

Children and Adolescents

• Not recommended for use in children under age 18

Pregnancy

• Insufficient data in humans to determine risk

• There is a risk of abnormal muscle movements and withdrawal symptoms in newborns whose mothers took an antipsychotic during the third trimester; symptoms may include agitation, abnormally increased or decreased muscle tone, tremor, sleepiness, severe difficulty breathing, and difficulty feeding

• Zotepine is not recommended during pregnancy

Breast Feeding

• Zotepine is not recommended during breast feeding

• Immediate postpartum period is a high-risk time for relapse of psychosis, so may consider treatment with another antipsychotic

ZOTEPINE: THE ART OF PSYCHOPHARMACOLOGY

Potential Advantages

• Norepinephrine reuptake blocking actions have theoretical benefits for cognition (attention) and for depression

Potential Disadvantages

• Patients not compliant with 3 times daily dosing

• Patients requiring rapid onset of antipsychotic action

• Patients with uncontrolled seizures

Primary Target Symptoms

• Positive symptoms of psychosis

• Negative symptoms of psychosis

• Cognitive functioning

• Depressive symptoms

Pearls

✽ Zotepine inhibits norepinephrine reuptake, which may have implications for treatment of depression, as well as for cognitive symptoms of schizophrenia

• Risks of diabetes and dyslipidemia not well studied for zotepine, but known significant weight gain suggests the need for careful monitoring during zotepine treatment

• Not as well investigated in bipolar disorder, but its mechanism of action suggests efficacy in acute bipolar mania

Suggested Reading

Ackenheil M. [The biochemical effect profile of zotepine in comparison with other neuroleptics]. Fortschr Neurol Psychiatr 1991;59(Suppl 1):S2–9.

Fenton M, Morris S, De-Silva P, Bagnall A, Cooper SJ, Gammelin G, Leitner M. Zotepine for schizophrenia. Cochrane Database Syst Rev 2000;(2):CD001948.

Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug Saf 2000;22(3):195–214.

ZUCLOPENTHIXOL

ZUCLOPENTHIXOL: THERAPEUTICS

Brands

• Clopixol

• Clopixol-Acuphase

see index for additional brand names

Generic?

No

Class

• Conventional antipsychotic (neuroleptic, thioxanthene, dopamine 2 antagonist)

Commonly Prescribed for

(bold for FDA approved)

• Acute schizophrenia (oral, acetate injection)

• Maintenance treatment of schizophrenia (oral, decanoate injection)

• Bipolar disorder

• Aggression

How the Drug Works

• Blocks dopamine 2 receptors, reducing positive symptoms of psychosis

How Long Until It Works

• For injection, psychotic symptoms can improve within a few days, but it may take 1–2 weeks for notable improvement

• For oral formulation, psychotic symptoms can improve within 1 week, but may take several weeks for full effect on behavior

If It Works

• Most often reduces positive symptoms in schizophrenia but does not eliminate them

• Most schizophrenic patients do not have a total remission of symptoms but rather a reduction of symptoms by about a third

• Continue treatment in schizophrenia until reaching a plateau of improvement

• After reaching a satisfactory plateau, continue treatment for at least a year after first episode of psychosis in schizophrenia

• For second and subsequent episodes of psychosis in schizophrenia, treatment may need to be indefinite

• Reduces symptoms of acute psychotic mania but not proven as a mood stabilizer or as an effective maintenance treatment in bipolar disorder

• After reducing acute psychotic symptoms in mania, switch to a mood stabilizer and/or an atypical antipsychotic for mood stabilization and maintenance

Соседние файлы в предмете [НЕСОРТИРОВАННОЕ]